Abarelix
FDA-approved product (powder, intramuscular), marketed as Plenaxis.
- Registered studies
- 5
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Other hormone antagonists and related agents
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA67.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae34.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis62.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
5registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Abarelix with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives64.9% AI-predicted activityagainst MRSALab records exist50+ registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more64.9% AI-predicted activityagainst MRSA50+ registered studies
- Naldemedine TosylateExisting use: Constipation, Constipation disorder64.8% AI-predicted activityagainst MRSA1 registered study
- Vorapaxar SulfateExisting use: Myocardial infarction, Peripheral arterial disease, Recurrent thrombophlebitis and 1 more64.8% AI-predicted activityagainst MRSA15 registered studies
- Rimegepant SulfateExisting use: Migraine disorder64.7% AI-predicted activityagainst MRSA50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency64.6% AI-predicted activityagainst MRSA7 registered studies
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction64.5% AI-predicted activityagainst MRSA1 registered study
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma64.4% AI-predicted activityagainst MRSA3 registered studies
- Isavuconazonium SulfateExisting use: Aspergillosis, Mucormycosis64.3% AI-predicted activityagainst MRSA50+ registered studies
- Nirogacestat HydrobromideExisting use: Gastrointestinal desmoid tumor64.2% AI-predicted activityagainst MRSA1 registered study
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more64.2% AI-predicted activityagainst MRSA50+ registered studies
- Etrasimod ArginineExisting use: Ulcerative colitis64.1% AI-predicted activityagainst MRSANo documented evidence found
Registered studies
A registration describes a study; it does not establish a positive result.
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
NCT06379217 · start 2024-07-29
Registered record
- Registry ID
- NCT06379217
- Conditions
- Metastatic Neuroendocrine Prostate Cancer
- Interventions
- [68Ga]Ga-PSMA-11; [68Ga]GA-DOTA-TATE; [68Ga]Ga-NeoB; [177Lu]Lu-PSMA-617; [177Lu]Lu-DOTA-TATE; [177Lu]Lu-NeoB; L-Lysine HCl-L-Arginine HCl, 2.5 %,; Gonadotropin-releasing hormone (GnRH) analogues; GnRH antagonists; Antiemetics & antinauseants; Metoclopramide
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Active not recruiting
- Start
- 2024-07-29
- Completion
- 2026-08-31
- Enrolment
- 31
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMetastatic Neuroendocrine Prostate CancerIntervention[68Ga]Ga-PSMA-11; [68Ga]GA-DOTA-TATE; [68Ga]Ga-NeoB; [177Lu]Lu-PSMA-617 +7 morePhasePhase 1Registry statusActive not recruitingDiagnosis of Pelvic Endometriosis in MRI
NCT06157528 · start 2023-12-20
Registered record
- Registry ID
- NCT06157528
- Conditions
- Endometriosis
- Interventions
- Magnetic resonance imaging
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Not yet recruiting
- Start
- 2023-12-20
- Completion
- 2029-12
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEndometriosisInterventionMagnetic resonance imagingPhaseNot applicableRegistry statusNot yet recruitingThe Plenaxis® Experience Study
NCT00103623 · start 2004-06
Registered record
- Registry ID
- NCT00103623
- Conditions
- Prostate Cancer
- Interventions
- Plenaxis
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Suspended
- Start
- 2004-06
- Completion
- 2008-12
- Enrolment
- 2,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionPlenaxisPhasePhase 4Registry statusSuspendedStudy of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
NCT00100243 · start 2004-05
Registered record
- Registry ID
- NCT00100243
- Conditions
- Prostate Cancer
- Interventions
- Plenaxis
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2004-05
- Completion
- 2005-09
- Enrolment
- 22
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionPlenaxisPhasePhase 2Registry statusCompletedAbarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
NCT00841113 · start 1999-01
Registered record
- Registry ID
- NCT00841113
- Conditions
- Prostate Cancer
- Interventions
- Abarelix; Goserelin plus Bicalutamide
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 1999-01
- Completion
- 2003-02
- Enrolment
- 177
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CancerInterventionAbarelix; Goserelin plus BicalutamidePhasePhase 3Registry statusCompleted